Ensuring Patients' Informed Access to Noninvasive Prenatal Testing

Study Summary

Noninvasive prenatal genetic testing (NIPT) is an important new screening test option provided to pregnant women in the first trimester of pregnancy. The advantage of this screen is that is provides information about the risk of trisomy 13, trisomy 18, and trisomy 21 with greater accuracy than conventional screens. At the same time, NIPT can produce information about the risk of a cohort of other fetal genetic variants, including sex chromosome aneuploidies and microdeletion syndromes. While not yet clinically available for whole exome sequencing, the potential for this next clinical application already exists. The challenge is that, while this is an important new test, there are little data about how to best structure patient-centered decisions about NIPTs use, including decisions if to use this screen and how the information may directly inform subsequent prenatal care decisions. The purpose of this study is to gain formative data about current practice patterns with respect to how NIPT is discussed in the clinical visit and to use these data to help inform best practices for NIPTs continued use in the clinical setting.

Primary Outcome

This will be measured using the OPTIONS scale, a validated scale developed to measure different components of a shared decision-making process in a clinical encounter as part of a direct observation approach.

Conditions Studied

Interventions

• BEHAVIORAL Usual care
• BEHAVIORAL NEST

Study Locations (2)